218449-63-9 Usage
Uses
Used in Pharmaceutical Industry:
[2-(3,4-DIFLUOROPHENYL)-2-HYDROXYETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is used as a potential drug candidate for the treatment of various diseases. Its unique chemical structure allows it to interact with biological targets, making it a promising option for the development of new therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, [2-(3,4-DIFLUOROPHENYL)-2-HYDROXYETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is used as a reagent or intermediate in the synthesis of other compounds. Its difluorophenyl group and carbamic acid ester functionality provide valuable synthetic handles for the preparation of a range of chemical products.
Overall, [2-(3,4-DIFLUOROPHENYL)-2-HYDROXYETHYL]-CARBAMIC ACID 1,1-DIMETHYLETHYL ESTER is a versatile chemical with potential uses in various industries, including pharmaceuticals and organic chemistry, due to its unique chemical structure and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 218449-63-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,4,4 and 9 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 218449-63:
(8*2)+(7*1)+(6*8)+(5*4)+(4*4)+(3*9)+(2*6)+(1*3)=149
149 % 10 = 9
So 218449-63-9 is a valid CAS Registry Number.
218449-63-9Relevant academic research and scientific papers
Oxazolidinones as alpha 1A receptor antagonists
-
, (2008/06/13)
This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
